Shanghai, China, and Lexington, MA., - August 3, 2023 - NeuShen Therapeutics (the “Company”), a global biotechnology company focused on developing innovative treatments for central nervous system (CNS) disorders with a dual-platform strategy consisting of small molecule discovery and AAV-based gene therapy, today announced that a poster featuring the Company’s proprietary novel KCNQ2/3 selective activator NS-041 will be presented at the 2023 American Chemical Society (ACS) Fall Meeting, which takes place during August 13-17 in San Francisco, CA.

Presentation Details:

Presentation Title: Voltage Gated Potassium Channel Activator for Resistant Epilepsy

Presenting Author: Dr. Lingyun Wu, Senior Vice President of Discovery Chemistry, NeuShen Therapeutics

Poster Number: 3662

Session: General Posters I, Division of Medicinal Chemistry

Location: Hall F, South Building, Moscone Center

Date & Time: August 13, 2023, 7:00 pm – 09:00 pm PT

Abstract

A novel KCNQ2/3 selective activator, NS-041, has been identified, with IND-enabling development and plans for clinical trials in the US and China being currently prepared. This compound can significantly lower channel open voltage and enhance the threshold of action potential. NS-041 also exhibited favorable ADME/PK properties and is an ideal candidate for daily oral dose. Furthermore, this compound was evaluated in various seizure models, including MES, PTZ, and 6Hz mice models, and robust antiseizure efficacy was cross-confirmed. Safety evaluations were performed for both CNS side effects and repeat dosing general toxicity, demonstrating superior results when compared to similar compounds. Overall, NS-041 exhibited a good safety window and was accepted as a development candidate suitable for clinical trials. Additionally, multiple studies have exhibited its potential for treating treatment-resistant depression. More details will be presented at the poster presentation.

About NeuShen Therapeutics

NeuShen Therapeutics is a global biotechnology company focused on innovative drug research and development to address central nervous system disorders, using a dual-platform strategy consisting of small molecule discovery and AAV-based gene therapy. With operations in Shanghai, China and Lexington, MA., NeuShen boasts a world-class R&D team in CNS field and is honored to be advised by an outstanding board of directors and scientific advisory board.